接受VA ECMO治疗心源性休克患者的大出血与血制品使用:多中心观察性研究(OBLEX)
这项前瞻性、研究者发起的纵向观察性队列研究纳入12个ECMO中心、3大洲的545例VA ECMO患者(ECPR 149例、心脏外科术后169例、心源性休克227例),2019至2022年入组,住院死亡率46%。2796天内记录到286例(52%)患者发生406次大出血事件,心脏外科术后和ECPR患者事件更频繁且更早出现。88%患者接受红细胞输注(1.27 U/天,95%CI 1.22–1.31),心脏外科术后和ECPR患者输注显著更多;血小板输注率在心脏外科术后组最高(0.58 U/天,95%CI 0.53–0.64)。输血前血红蛋白和血小板计数在各亚组间无差异,平均分别为78 g/L(IQR 73–84)和58×10^9/L(IQR 37–85)。83%(95%CI 80–87%)患者在24小时内启动全身抗凝,心源性休克组最常用(90%,CI 85–95%)。ECPR(IRR 1.50,95%CI 1.19–1.89)和既往抗血小板药物使用(IRR 1.43,95%CI 1.13–1.80)是红细胞输注的独立基线预测因素;与心肌梗死相比,心肌炎和肺栓塞与较低的输血率相关(IRR分别为0.57(0.37–0.89)和0.67(0.45–1.00))。作者结论认为出血并发症在不同临床亚组间存在差异,红细胞输注暴露远高于其他危重人群,输血实践存在差异且并不总是遵循国际指南。
要点
- 545例VA ECMO患者中52%(286例)发生大出血,共406次事件,住院死亡率46%。
- 88%患者接受红细胞输注,平均1.27 U/天(95%CI 1.22–1.31),心脏外科术后和ECPR患者输注显著更多。
- 输血前血红蛋白平均78 g/L(IQR 73–84),血小板计数平均58×10^9/L(IQR 37–85),各亚组间无差异。
- ECPR(IRR 1.50,95%CI 1.19–1.89)和既往抗血小板药物使用(IRR 1.43,95%CI 1.13–1.80)是红细胞输注的独立基线预测因素。
- 83%(95%CI 80–87%)患者在24小时内启动全身抗凝,心源性休克组最常用(90%,CI 85–95%)。
适用人群与场景
- 接受VA ECMO的成人患者,分为三个预设亚组:心肺复苏期间启动VA ECMO(ECPR)、心脏外科术后(CTS)、心源性休克(CS)。
研究设计与关键结果
- 前瞻性、研究者发起的纵向观察性队列研究,纳入12个ECMO中心、3大洲的545例患者(ECPR 149例、CTS 169例、CS 227例),2019至2022年入组。
- 住院死亡率46%;2796天内记录到286例(52%)患者发生406次大出血事件,CTS和ECPR患者事件更频繁且更早出现。
- 88%患者接受红细胞输注,平均1.27 U/天(95%CI 1.22–1.31),CTS和ECPR患者输注显著更多;血小板输注率在CTS组最高(0.58 U/天,95%CI 0.53–0.64)。
- 输血前血红蛋白平均78 g/L(IQR 73–84),血小板计数平均58×10^9/L(IQR 37–85),各亚组间无差异;大出血日输血前血小板计数仅略高(74×10^9/L,IQR 50–104)。
- 83%(95%CI 80–87%)患者在24小时内启动全身抗凝,心源性休克组最常用(90%,CI 85–95%)。
- 红细胞输注的独立基线预测因素为ECPR(IRR 1.50,95%CI 1.19–1.89)和既往抗血小板药物使用(IRR 1.43,95%CI 1.13–1.80);与心肌梗死相比,心肌炎和肺栓塞与较低输血率相关(IRR分别为0.57(0.37–0.89)和0.67(0.45–1.00))。
证据类型、等级与局限
- 证据类型:前瞻性、多中心观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- VA ECMO患者大出血和红细胞输注暴露远高于其他危重人群,ECPR和既往抗血小板治疗患者输血需求更高,床旁应据此提高对出血和输血的警惕。
- 作者认为输血实践存在差异且并不总是遵循国际指南。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Haemorrhage and blood product usage are common in venoarterial extracorporeal membrane oxygenation (VA ECMO) and associated with increased mortality. METHODS: A prospective, investigator-initiated, longitudinal observational cohort study on major haemorrhagic events in 12 ECMO centres from 3 continents for three predefined subgroups (VA ECMO initiated during cardio-pulmonary resuscitation (ECPR), after cardiothoracic surgery (CTS), for cardiogenic shock (CS)). The aim was to describe haemorrhagic complications as well as transfusion practice and anticoagulation for the whole population as well as the subgroups. In addition, independent baseline predictors for red blood cell (RBC) transfusions were evaluated. RESULTS: 545 prospective patients were included between 2019 and 2022 (ECPR 149, CTS 169, CS 227). Hospital mortality was 46%. Over 2796 days 406 major haemorrhage events in 286 (52%) patients were recorded. CTS and ECPR patients had more frequent events occurring earlier in their course. 88% received RBC transfusions (1.27 (95%CI 1.22 – 1.31) units/day) with significantly more transfusions for CTS and ECPR patients. Platelet transfusion rates were highest in the CTS group (0.58 (95%CI 0.53–0.64) units/day). Haemoglobin and platelet count prior to transfusion were independent of subgroups and averaged (78 g/L (IQR 73, 84), 58 × 10^9/L (IQR 37, 85), respectively). However, platelet count prior transfusion was only marginally higher on days with major haemorrhage (74 × 10^9/L (IQR 50, 104). Systemic anticoagulation was started within the first 24 h in 83% (95% CI 80–87%) of patients, most frequently in CS patients (90%, CI 85–95%). Independent baseline predictors for RBC transfusion were ECPR (IRR 1.50, 95%CI 1.19–1.89) and prior use of antiplatelets (IRR: 1.43, 95%CI 1.13–1.80). Myocarditis and pulmonary embolism were associated with a lower rate of transfusion when compared to myocardial infarct (IRR: 0.57 (0.37–0.89), IRR: 0.67 (0.45–1.00, respectively). CONCLUSION: Haemorrhagic complications differ in clinical subgroups and RBC transfusion exposure is by far higher than in other critically unwell populations. We identified ECPR and antiplatelet therapy as additional predictors. Transfusion practice for RBC and platelets is variable and does not always follow international guidelines.
参考来源
- Buscher H, Thao LTP, Martucci G, et al. Major haemorrhage and blood product utilisation in patients receiving VA ECMO for cardiogenic shock: a multicentre observational study (OBLEX). Crit Care. 2026. PMID: 41814336. doi:10.1186/s13054-026-05900-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。